

Detta är en bilaga till TLV:s rapport

## Genomgången av läkemedel mot depression

Allt informationsmaterial om genomgången finns att hämta på [www.tlv.se/depression](http://www.tlv.se/depression)

Rapport, sammanfattning och faktablad finns också att beställa via [registrator@tlv.se](mailto:registrator@tlv.se)

## Litteratursökning till metaanalys

Denna bilaga beskriver litteratursökningen till den metaanalys som finns publicerad i TLV:s rapport om genomgången av antidepressiva läkemedel.

Kriterierna för att inkludera eller exkludera en studie i den initiala systematiska genomgången var följande:

- Endast direkt jämförande, randomiserade studier (dvs. studier med aktiv kontroll, men en placeboarm kunde också finnas)
- Moderat till svår egentlig depression (*moderate to severe major depressive disorder*) MADRS  $\geq$  18 eller HAMD  $\geq$  15
- Ingen psykiatrisk samsjuklighet (framför allt psykoser och bipolär sjukdom)
- Patienter 18 år eller äldre
- Studielängd mer än 6 veckor
- Terapeutiska doser av de studerade läkemedlen
- Patienterna fick inte ta läkemedel som kunde störa tolkningen av studiedata (t.ex. litium)
- Studien måste rapportera remission som en HAMD-poäng  $\leq$  7 eller 8 eller som en MADRS-poäng  $\leq$  12.

## Initial sökning

PubMed söktes (senaste uppdatering 071220) med sökorden "Antidepressive Agents" [MeSH] och "Depressive Disorder" [MeSH]. Limits sattes till: publicerat/entered in PubMed efter 2005, RCT, Humans, all adults, samt språk = engelska.

Denna sökning gav cirka 170 träffar. Efter genomläsning av titlar och abstracts återstod elva artiklar. Tio av dessa uppfyllde inklusions/exklusionskriterierna [1–10] och en exkluderades [11].

The Cochrane Central Register of Controlled Trials söktes (senaste uppdatering 071206) med sökorden "antidepressive agents" och "depressive disorder" med begränsningen i tid till 2005 och senare. Resultatet blev 118 träffar, men efter genomläsning av abstracts konstaterades att ingen ny referens uppfyllde inklusionskriterierna.

### TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---

Företagen ombeds komma in med relevanta referenser i inledningen av genomgångarna av läkemedelssortimentet. Vid en handsökning av dessa inskickade referenslistor identifierades en studie, som också uppfyllde inklusionskriterierna [12].

### ***Kompletterande sökning med avseende på mirtazapin***

PubMed söktes för att identifiera head to head-studier med mirtazapin (senaste uppdatering 071220). De söktermer som användes var "mirtazapine" [MeSH] med limits språk=engelska, humans, all adults, randomized clinical trials. Sökningen gav ca 100 träffar. Efter genomläsning av titlar och abstracts återstod elva artiklar, varav nio inkluderades [13\_22] och en exkluderades [23]. Cochrane söktes med sökorden mirtazapine och depressive disorders vilket gav 61 träffar. Efter genomläsning av titlar och abstracts återstod en artikel ([24]), men den exkluderades efter en närmare granskning.

### ***Kompletterande sökning med avseende på reboxetin***

PubMed söktes för att identifiera head to head-studier med reboxetin (senaste uppdatering 080310). De söktermer som användes var "reboxetine" [MeSH] med limits språk=engelska, humans, all adults, randomized clinical trials. Sökningen gav 75 träffar. Cochrane söktes med sökorden "reboxetine" och depressive disorders vilket gav 16 träffar. Efter granskning av artiklarna återstod endast en studie som uppfyllde inklusionskriterierna [25].

### ***Opublicerade studier***

Opublicerade studier har sökts genom att skriva till företagen som marknadsför antidepressiva läkemedel i Sverige och fråga efter opublicerat material samt på de webbsidor där företagen kan lägga ut opublicerat material. De aktuella företagens hemsidor söktes, samt webbsidorna [www.clinicalstudyresults.org](http://www.clinicalstudyresults.org) och <http://www.centerwatch.com/patient/trials.html>.

Dessa sökningar identifierade ganska få helt opublicerade studier, men ett stort antal studier som publicerats endast som abstracts och även ett antal publicerade studier som inte fanns med i Machados metaanalys och som inte identifierats tidigare.

Från Wyeth inkom fjorton studier som inkluderades [7, 26\_38] samt tjugo som exkluderades: [39-58].

#### **TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET**

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---

Lundbeck inkom med sex studier som inkluderades: [8, 59\_61] [10, 62, 63].

Glaxo Smith Kline skickade in åtta studier som kunde inkluderas [64–71].

Eli Lilly skickade in sex studier som inkluderades; [9, 72–76] samt fem som exkluderades; [77–81].

## Referenser

1. Boulenger, J.P., et al., *A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients*. *Curr Med Res Opin*, 2006. **22**(7): p. 1331-41.
2. Colonna, L., H.F. Andersen, and E.H. Reines, *A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder*. *Curr Med Res Opin*, 2005. **21**(10): p. 1659-68.
3. Moore, N., H. Verdoux, and B. Fantino, *Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder*. *Int Clin Psychopharmacol*, 2005. **20**(3): p. 131-7.
4. Rossini, D., et al., *Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial*. *J Clin Psychopharmacol*, 2005. **25**(5): p. 471-5.
5. Schatzberg, A. and S. Roose, *A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression*. *Am J Geriatr Psychiatry*, 2006. **14**(4): p. 361-70.
6. Versiani, M., et al., *Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients*. *CNS Drugs*, 2005. **19**(2): p. 137-46.
7. Nemeroff, C.B. and M.E. Thase, *A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients*. *J Psychiatr Res*, 2007. **41**(3-4): p. 351-9.
8. Nierenberg, A.A., et al., *Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*. *Curr Med Res Opin*, 2007. **23**(2): p. 401-16.
9. Perahia, D.G., et al., *A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder*. *J Psychiatr Res*, 2007.
10. Ventura, D., et al., *Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial*. *Curr Med Res Opin*, 2007. **23**(2): p. 245-50.

### TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---

11. Baldomero, E.B., et al., *Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study*. *Depress Anxiety*, 2005. **22**(2): p. 68-76.
12. Wisner, K.L., et al., *Postpartum depression: a randomized trial of sertraline versus nortriptyline*. *J Clin Psychopharmacol*, 2006. **26**(4): p. 353-60.
13. Amini, H., et al., *Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial*. *J Clin Pharm Ther.*, 2005. **30**(2): p. 133-138.
14. Hong, C.J., et al., *A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients*. *J Clin Psychiatry*, 2003. **64**(8): p. 921-6.
15. Behnke, K., et al., *Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study*. *J Clin Psychopharmacol*, 2003. **23**(4): p. 358-64.
16. Wade, A., et al., *A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care*. *Int Clin Psychopharmacol*, 2003. **18**(3): p. 133-41.
17. Schatzberg, A.F., et al., *Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients*. *Am J Geriatr Psychiatry*, 2002. **10**(5): p. 541-50.
18. Guelfi, J.D., et al., *Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features*. *J Clin Psychopharmacol*, 2001. **21**(4): p. 425-31.
19. Benkert, O., A. Szegedi, and R. Kohlen, *Mirtazapine compared with paroxetine in major depression*. *J Clin Psychiatry*, 2000. **61**(9): p. 656-63.
20. Wheatley, D.P., et al., *Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group*. *J Clin Psychiatry*, 1998. **59**(6): p. 306-12.
21. Fava, M., et al., *A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR\*D report*. *Am J Psychiatry*, 2006. **163**(7): p. 1161-72.
22. Benkert, O., et al., *Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder*. *J Clin Psychopharmacol*, 2006. **26**(1): p. 75-8.
23. Leinonen, E., et al., *Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group*. *Int Clin Psychopharmacol*, 1999. **14**(6): p. 329-37.
24. Turan, M., et al., *Mirtazapine versus amitriptyline in treatment of major depressive disorder*. *A Journal of the European College of Neuropsychopharmacology (Abstracts of the 13th ECNP Congress, Munich, September 9-13, 2000)*, 2000. **10**: p. 228.
25. Schwartz, G., P. Such, and A. Schatzberg, *Reboxetine vs venlafaxine in the treatment of severe major depression* *European Neuropsychopharmacology*, 2002. **12 Suppl 3**: p. S204.

#### TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---

26. Tylee, A., et al., *A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice*. Primary Care Psychiatry, 1997. **3**: p. 51-58.
27. McPartlin, G., et al., *A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice*. Primary Care Psychiatry, 1998. **4**: p. 127-132.
28. Alves, C., I. Cachola, and J. Brandao, *Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression*. Primary Care Psychiatry, 1999. **5**(2): p. 57-63.
29. De Nayer, A., et al., *Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety*. Int J Neuropsychopharmacol, 2002. **5**(2): p. 115-20.
30. Tzanakaki, M., et al., *Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia*. Int Clin Psychopharmacol, 2000. **15**(1): p. 29-34.
31. Rudolph, R.L. and A.D. Feiger, *A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression*. J Affect Disord, 1999. **56**(2-3): p. 171-81.
32. Koornat, H. *Randomized, double-blind comparison of venlafaxine and fluoxetine for moderately depressed outpatients*. in *XXI:th Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP)*. 1998. Glasgow, Scotland.
33. Ballus, C., et al., *The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia*. Int Clin Psychopharmacol, 2000. **15**(1): p. 43-8.
34. Costa e Silva, J., *Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression*. J Clin Psychiatry, 1998. **59**(7): p. 352-7.
35. Mehtonen, O.P., et al., *Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group*. J Clin Psychiatry, 2000. **61**(2): p. 95-100.
36. Trivedi, M., et al. *Depression remission rates with venlafaxine XR vs SSRIs using treatment algorithms*. in *World Psychiatry Association*. 2005. Athens, Greece.
37. Sir, A., et al., *Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms*. J Clin Psychiatry, 2005. **66**(10): p. 1312-20.
38. Shelton, R.C., et al., *A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder*. J Clin Psychiatry, 2006. **67**(11): p. 1674-81.
39. Nemeroff, C.B. and M. Cantillon. *A comparison of venlafaxine vs fluoxetine or placebo in depressed outpatients*. in *XXII:th Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP 2000)*. 2000. Brussels, Belgium.
40. Casabona, G.M., V. Silenzi, and M. Guazzelli, *A randomized, double blind, comparison of venlafaxine ER and paroxetine in outpatients with moderate to severe major depression*. The Journal of the European College of Neuropsychopharmacology, 2002. **12**, supplement **3**: p. 208.
41. Dufour, A., et al., *Clinical acceptability of venlafaxine extended release and paroxetine in outpatients treated for depression by general practitioners*. J Europ Coll Neuropsychopharm 2001;11 (suppl 3);, 2001. **11** (suppl **3**): p. 224.

#### TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---

42. Mehtonen, O.-P., *A double-blind, randomized study of the efficacy and safety of venlafaxine extended release (ER) versus fluoxetine in outpatients with major depression*. The Journal of the European College of Neuropsychopharmacology, 2002. **12 (suppl 3)**: p. 253.
43. Lennox-Smith, A., et al. *A double blind trial of venlafaxine XR vs citalopram in patients with treatment resistant depression*. in *British Association for Psychopharmacology meeting*. 2001. Harrogate, UK.
44. Stevens, I., *Comparison of the efficacy and safety of venlafaxine and fluoxetine in GP patients with moderate to severe depression*. Biol. Psychiatry, 1997. **42 (suppl)**: p. 244S.
45. Hackett, D., E. Salinas, and A. Desmet. *Efficacy and safety of venlafaxine vs fluvoxamine in outpatients with major depression*. in *European College of Neuropsychopharmacology (ECNP)*. 1998. Paris, France.
46. Dierick, M., et al., *A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients*. Prog Neuropsychopharmacol Biol Psychiatry, 1996. **20(1)**: p. 57-71.
47. Salinas, E., *Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression*. Biol. Psychiatry, 1997. **42 (suppl)**: p. 244S.
48. Rudolph, R.L., et al., *Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study*. The Journal of the European College of Neuropsychopharmacology, 1998. **8 (suppl 2)**: p. S142.
49. Davidson, J.R., et al., *Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms*. Depress Anxiety, 2002. **16(1)**: p. 4-13.
50. Poirier, M.F. and P. Boyer, *Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison*. Br J Psychiatry, 1999. **175**: p. 12-6.
51. Clerc, G.E., P. Ruimy, and J. Verdeau-Palles, *A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group*. Int Clin Psychopharmacol, 1994. **9(3)**: p. 139-43.
52. Benattia, I., J. Musgnung, and J. Graepel. *Depression remission with venlafaxine XR or SSRIs using treatment algorithms*. in *World Congress of Family Doctors 13-17 oct*. 2004. Orlando, Florida.
53. Vieta, E., et al., *A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers*. J Clin Psychiatry, 2002. **63(6)**: p. 508-12.
54. Zanardi, R., et al., *Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study*. J Clin Psychiatry, 2000. **61(1)**: p. 26-9.
55. Oslin, D.W., et al., *Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents*. J Clin Psychiatry, 2003. **64(8)**: p. 875-82.
56. Keller, M. and e. al. *Recurrence prevention: Efficacy of two years of maintenance treatment with venlafaxine XR in patients with recurrent unipolar major depression*. in *American Psychiatric Association, May 20-25*. 2006. Toronto, Canada.
57. Baca, E., et al., *Venlafaxine extended-release in patients older than 80 years with depressive syndrome*. Int J Geriatr Psychiatry, 2006. **21(4)**: p. 337-43.

#### TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---

58. Diaz-Martinez, A., et al., *A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients*. Clin Ther, 1998. **20**(3): p. 467-76.
59. Baldwin, D.S., et al., *A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder*. Int Clin Psychopharmacol, 2006. **21**(3): p. 159-69.
60. Kasper, S., H. de Swart, and H. Friis Andersen, *Escitalopram in the treatment of depressed elderly patients*. Am J Geriatr Psychiatry, 2005. **13**(10): p. 884-91.
61. Lepola, U.M., H. Loft, and E.H. Reines, *Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care*. Int Clin Psychopharmacol, 2003. **18**(4): p. 211-7.
62. Jonas, J., et al., *Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder*. Neuropsychopharmacology, 2006. **31** (suppl): p. S166.
63. Wade, A. and E.H. Reines, *A comparative study of escitalopram and duloxetine in depressed patients. Abstract + Data on file, in 48th Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology 2007*: Elinore, DK.
64. De Wilde, J., et al., *A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients*. Acta Psychiatr Scand, 1993. **87**(2): p. 141-5.
65. Gagiano, C., *A double-blind comparison of paroxetine and fluoxetine in patients with major depression*. Br J Clin Res, 1993. **4**: p. 145-152.
66. Geretsegger, C., F. Böhmer, and M. Ludwig, *Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects*. Int Clin Psychopharmacol., 1994. **9**: p. 25-29.
67. Laurelle, M., et al., *A multicenter double-blind comparative study between paroxetine and maprotiline in major depression*. Eur. Neuropsychopharmacol., 1991. **1**(3): p. 439S.
68. Moon, C.A. and M. Vince, *Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine*. Br J Clin Pract, 1996. **50**(5): p. 240-4.
69. Tignol, J., *A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression*. J Clin Psychopharmacol, 1993. **13**(6 Suppl 2): p. 18S-22S.
70. Unpublished, Study No: 29060/056/UK, GSK.
71. Unpublished/GSK, Study No: SER-CHN-1.
72. Detke, M.J., et al., *Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial*. Eur Neuropsychopharmacol, 2004. **14**(6): p. 457-70.
73. Goldstein, D.J., et al., *Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine*. J Clin Psychopharmacol, 2004. **24**(4): p. 389-99.
74. Goldstein, D.J., et al., *Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial*. J Clin Psychiatry, 2002. **63**(3): p. 225-31.
75. Perahia, D.G., et al., *Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial*. Eur Psychiatry, 2006. **21**(6): p. 367-78.
76. Unpublished, Study No: F1J-MC-HMAT Study group A. 2004, EliLilly: Indianapolis, IN.

#### TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---

77. Hirschfeld, R.M., et al. *Efficacy of duloxetine versus combined SSRIs (fluoxetine, paroxetine, escitalopram) and placebo in the treatment of major depressive disorder*. in APA. 2006.
78. Thase, M.E., et al. *Remission in placebo-controlled trials of duloxetine with an SSRI comparator*. in American Psychiatric Association. 2003. San Francisco, USA.
79. Dunner, D.L., et al., *Clinical consequences of initial duloxetine dosing strategies : Comparison of 30 and 60 mg QD starting doses*. Current therapeutic research, 2005. **66**(6): p. 522-540.
80. Delgado, P.L., et al., *Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder*. J Clin Psychiatry, 2005. **66**(6): p. 686-92.
81. Nelson, J.C., et al., *The Safety and Tolerability of Duloxetine Compared With Paroxetine and Placebo: A Pooled Analysis of 4 Clinical Trials*. Prim Care Companion J Clin Psychiatry, 2006. **8**(4): p. 212-219.

#### TANDVÅRDS- OCH LÄKEMEDELSFÖRMÅNSVERKET

---

Box 55 [Sundbybergsvägen 1], 171 11 Solna

---

Telefon: 08 568 420 50, Fax: 08 568 420 99, [registrator@tlv.se](mailto:registrator@tlv.se), [www.tlv.se](http://www.tlv.se)

---

Org. nr 202 100-5364

---